MAPT and Alzheimer disease: This may prove cost-effective in trials involving preclinical and prodromal AD given that a baseline tau PET scan would anyway be required if using longitudinal tau PET as an end point and that plasma p-tau217 is comparatively easy and inexpensive to measure.